Hudson Capital Management LLC Has $5.18 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Hudson Capital Management LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 56,102 shares of the biopharmaceutical company’s stock after selling 2,576 shares during the period. Gilead Sciences comprises 1.6% of Hudson Capital Management LLC’s holdings, making the stock its 24th largest position. Hudson Capital Management LLC’s holdings in Gilead Sciences were worth $5,182,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Bartlett & CO. Wealth Management LLC lifted its position in Gilead Sciences by 149.1% during the fourth quarter. Bartlett & CO. Wealth Management LLC now owns 8,697 shares of the biopharmaceutical company’s stock worth $803,000 after acquiring an additional 5,205 shares during the last quarter. Albion Financial Group UT lifted its position in Gilead Sciences by 182.7% during the fourth quarter. Albion Financial Group UT now owns 783 shares of the biopharmaceutical company’s stock worth $72,000 after acquiring an additional 506 shares during the last quarter. Advisory Alpha LLC acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $260,000. XML Financial LLC acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $203,000. Finally, Genesis Private Wealth LLC acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $362,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on GILD shares. Morgan Stanley upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. BMO Capital Markets raised their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. UBS Group raised their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Barclays raised their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $97.96.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 456,234 shares of company stock valued at $42,130,461. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 0.1 %

Gilead Sciences stock opened at $93.04 on Thursday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The firm has a 50 day moving average price of $91.62 and a 200-day moving average price of $84.57. The company has a market capitalization of $115.95 billion, a P/E ratio of 1,033.78, a P/E/G ratio of 1.31 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the firm earned $2.29 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.